Avammune Lifesciences

Avammune Lifesciences is the India-based operating entity of Avammune, an oncology-focused drug discovery company developing first-in-class and best-in-class therapies for hard-to-treat solid tumors. The company emphasizes small-molecule cancer therapeutics and has disclosed programs targeting ENPP1 and ADAR1 p150, along with a tumor-targeted radioligand therapy program. Avammune positions itself as a modality-agnostic but discovery-platform-driven biotech that uses bioinformatics, computational chemistry, medicinal chemistry, and high-throughput biology to generate oncology assets. Its strategy appears centered on reshaping the tumor microenvironment, overcoming immune evasion, and enabling early proof-of-concept partnerships. The company raised a $12 million Series A round in 2025 to support IP expansion and clinical development of its lead ENPP1 inhibitor program.